Gene signatures useful for informing therapeutic choices have been developed for early stage BC [3,4], and the dependence on ER, PR or HER2 activity is currently exploited for the application of targeted therapies [1], which have considerably improved patients’ survival. Here, PGR is linked to breast cancer.